Subtype
Intestinal Carcinoma
CI-CAN-00002922Explore in graph →
409 active trials5 approved drugs22 evidence items
- NCIt
- C227934
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002922Explore in graph →
Clinical trials
1,268 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (150)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02713373 | Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 45 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT00416351 | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT02402842 | Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma(Epitopes-HPV02) | completed | Phase 2 | 70 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT03403634 | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03142516 | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status(OPALO) | completed | Phase 2 | 20 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02811497 | Study of Azacitidine and Durvalumab in Advanced Solid Tumors(METADUR) | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02641691 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum(NORMAL-R) | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03152565 | Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients(AVEVAC) | completed | Phase 1 / Phase 2 | 28 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT01208103 | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00437268 | A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | completed | Phase 2 | 26 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT01674309 | First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis | completed | Phase 2 | 65 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT00321685 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00409994 | Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer | completed | Phase 1 / Phase 2 | 44 | Maastricht Radiation OncologyOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01285778 | Vectibix for the Treatment of Anal Cancer(VITAL) | completed | Phase 2 | 58 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT01462513 | L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases(LICC) | completed | Phase 2 | 122 | Prof. Dr. Carl SchimanskiOTHER | 2 | Feb 13, 2018 | clinicaltrials |
| NCT01139138 | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer(PIE) | completed | Phase 1 / Phase 2 | 49 | The Queen Elizabeth HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00682786 | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma | completed | Phase 2 | 135 | Washington University School of MedicineOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00433550 | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer | completed | Phase 2 | 33 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01333709 | Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma(GRECCAR4) | completed | Phase 2 | 150 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00582660 | Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib(UAB0040) | completed | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00828984 | Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00362102 | A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma | completed | Phase 2 | 38 | Eli Lilly and CompanyINDUSTRY | 0 | Nov 22, 2016 | clinicaltrials |
| NCT00753675 | Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer(VANGOGH) | completed | Phase 2 | 174 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00336856 | Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy | completed | Phase 2 | 35 | University of PittsburghOTHER | 1 | Jul 12, 2016 | clinicaltrials |
| NCT01675128 | ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT01703910 | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic | completed | Phase 2 | 29 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00660699 | A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT02423226 | Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer | completed | Phase 2 | 56 | The First People's Hospital of ChangzhouOTHER | 0 | Apr 22, 2015 | clinicaltrials |
| NCT00032110 | Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01277406 | 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma(SHORE) | completed | Phase 1 / Phase 2 | 17 | 4SC AGINDUSTRY | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00551421 | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 31, 2015 | clinicaltrials |
| NCT00704600 | Nelfinavir, a Phase I/Phase II Rectal Cancer Study(Nelfinavir) | completed | Phase 1 / Phase 2 | 15 | Maastricht Radiation OncologyOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT01554059 | Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients(New Beat) | completed | Phase 2 | 25 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT00589563 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | completed | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Oct 6, 2022source: clinicaltrials